001package org.hl7.fhir.dstu2016may.model.codesystems; 002 003 004 005 006/* 007 Copyright (c) 2011+, HL7, Inc. 008 All rights reserved. 009 010 Redistribution and use in source and binary forms, with or without modification, 011 are permitted provided that the following conditions are met: 012 013 * Redistributions of source code must retain the above copyright notice, this 014 list of conditions and the following disclaimer. 015 * Redistributions in binary form must reproduce the above copyright notice, 016 this list of conditions and the following disclaimer in the documentation 017 and/or other materials provided with the distribution. 018 * Neither the name of HL7 nor the names of its contributors may be used to 019 endorse or promote products derived from this software without specific 020 prior written permission. 021 022 THIS SOFTWARE IS PROVIDED BY THE COPYRIGHT HOLDERS AND CONTRIBUTORS "AS IS" AND 023 ANY EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED 024 WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE ARE DISCLAIMED. 025 IN NO EVENT SHALL THE COPYRIGHT HOLDER OR CONTRIBUTORS BE LIABLE FOR ANY DIRECT, 026 INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, OR CONSEQUENTIAL DAMAGES (INCLUDING, BUT 027 NOT LIMITED TO, PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES; LOSS OF USE, DATA, OR 028 PROFITS; OR BUSINESS INTERRUPTION) HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, 029 WHETHER IN CONTRACT, STRICT LIABILITY, OR TORT (INCLUDING NEGLIGENCE OR OTHERWISE) 030 ARISING IN ANY WAY OUT OF THE USE OF THIS SOFTWARE, EVEN IF ADVISED OF THE 031 POSSIBILITY OF SUCH DAMAGE. 032 033*/ 034 035// Generated on Sun, May 8, 2016 03:05+1000 for FHIR v1.4.0 036 037 038import org.hl7.fhir.exceptions.FHIRException; 039 040public enum V3ObservationInterpretation { 041 042 /** 043 * Codes that specify interpretation of genetic analysis, such as "positive", "negative", "carrier", "responsive", etc. 044 */ 045 _GENETICOBSERVATIONINTERPRETATION, 046 /** 047 * The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder. 048 */ 049 CAR, 050 /** 051 * The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder. 052 053 054 055 Deprecation Comment: 056 This code is currently the same string as the print name for this concept and is inconsistent with the conventions being used for the other codes in the coding system, as it is a full word with initial capitalization, rather than an all upper case mnemonic. The recommendation from OO is to deprecate the code "Carrier" and to add "CAR" as the new active code representation for this concept. 057 */ 058 CARRIER, 059 /** 060 * Interpretations of change of quantity and/or severity. At most one of B or W and one of U or D allowed. 061 */ 062 _OBSERVATIONINTERPRETATIONCHANGE, 063 /** 064 * The current result or observation value has improved compared to the previous result or observation value (the change is significant as defined in the respective test procedure). 065 066 [Note: This can be applied to quantitative or qualitative observations.] 067 */ 068 B, 069 /** 070 * The current result has decreased from the previous result for a quantitative observation (the change is significant as defined in the respective test procedure). 071 */ 072 D, 073 /** 074 * The current result has increased from the previous result for a quantitative observation (the change is significant as defined in the respective test procedure). 075 */ 076 U, 077 /** 078 * The current result or observation value has degraded compared to the previous result or observation value (the change is significant as defined in the respective test procedure). 079 080 [Note: This can be applied to quantitative or qualitative observations.] 081 */ 082 W, 083 /** 084 * Technical exceptions resulting in the inability to provide an interpretation. At most one allowed. Does not imply normality or severity. 085 */ 086 _OBSERVATIONINTERPRETATIONEXCEPTIONS, 087 /** 088 * The result is below the minimum detection limit (the test procedure or equipment is the limiting factor). 089 090 Synonyms: Below analytical limit, low off scale. 091 */ 092 LESS_THAN, 093 /** 094 * The result is above the maximum quantifiable limit (the test procedure or equipment is the limiting factor). 095 096 Synonyms: Above analytical limit, high off scale. 097 */ 098 GREATER_THAN, 099 /** 100 * A valid result cannot be obtained for the specified component / analyte due to the presence of anti-complementary substances in the sample. 101 */ 102 AC, 103 /** 104 * There is insufficient evidence that the species in question is a good target for therapy with the drug. A categorical interpretation is not possible. 105 106 [Note: A MIC with "IE" and/or a comment may be reported (without an accompanying S, I or R-categorization).] 107 */ 108 IE, 109 /** 110 * A result cannot be considered valid for the specified component / analyte or organism due to failure in the quality control testing component. 111 */ 112 QCF, 113 /** 114 * A valid result cannot be obtained for the specified organism or cell line due to the presence of cytotoxic substances in the sample or culture. 115 */ 116 TOX, 117 /** 118 * Interpretation of normality or degree of abnormality (including critical or "alert" level). Concepts in this category are mutually exclusive, i.e., at most one is allowed. 119 */ 120 _OBSERVATIONINTERPRETATIONNORMALITY, 121 /** 122 * The result or observation value is outside the reference range or expected norm (as defined for the respective test procedure). 123 124 [Note: Typically applies to non-numeric results.] 125 */ 126 A, 127 /** 128 * The result or observation value is outside a reference range or expected norm at a level at which immediate action should be considered for patient safety (as defined for the respective test procedure). 129 130 [Note: Typically applies to non-numeric results. Analogous to critical/panic limits for numeric results.] 131 */ 132 AA, 133 /** 134 * The result for a quantitative observation is above a reference level at which immediate action should be considered for patient safety (as defined for the respective test procedure). 135 136 Synonym: Above upper panic limits. 137 */ 138 HH, 139 /** 140 * The result for a quantitative observation is below a reference level at which immediate action should be considered for patient safety (as defined for the respective test procedure). 141 142 Synonym: Below lower panic limits. 143 */ 144 LL, 145 /** 146 * The result for a quantitative observation is above the upper limit of the reference range (as defined for the respective test procedure). 147 148 Synonym: Above high normal 149 */ 150 H, 151 /** 152 * A test result that is significantly higher than the reference (normal) or therapeutic interval, but has not reached the critically high value and might need special attention, as defined by the laboratory or the clinician.[Note: This level is situated between 'H' and 'HH'.] 153 154 155 Deprecation Comment: The code 'H>' is being deprecated in order to align with the use of the code 'HU' for "Very high" in V2 Table 0078 "Interpretation Codes". 156 157 [Note: The use of code 'H>' is non-preferred, as this code is deprecated and on track to be retired; use code 'HU' instead. 158 */ 159 H_, 160 /** 161 * A test result that is significantly higher than the reference (normal) or therapeutic interval, but has not reached the critically high value and might need special attention, as defined by the laboratory or the clinician. 162 */ 163 HU, 164 /** 165 * The result for a quantitative observation is below the lower limit of the reference range (as defined for the respective test procedure). 166 167 Synonym: Below low normal 168 */ 169 L, 170 /** 171 * A test result that is significantly lower than the reference (normal) or therapeutic interval, but has not reached the critically low value and might need special attention, as defined by the laboratory or the clinician.[Note: This level is situated between 'L' and 'LL'.] 172 173 174 Deprecation Comment: The code 'L<' is being deprecated in order to align with the use of the code 'LU' for "Very low" in V2 Table 0078 "Interpretation Codes". 175 176 [Note: The use of code 'L<' is non-preferred, as this code is deprecated and on track to be retired; use code 'LU' instead. 177 */ 178 L_, 179 /** 180 * A test result that is significantly lower than the reference (normal) or therapeutic interval, but has not reached the critically low value and might need special attention, as defined by the laboratory or the clinician. 181 */ 182 LU, 183 /** 184 * The result or observation value is within the reference range or expected norm (as defined for the respective test procedure). 185 186 [Note: Applies to numeric or non-numeric results.] 187 */ 188 N, 189 /** 190 * Interpretations of anti-microbial susceptibility testing results (microbiology). At most one allowed. 191 */ 192 _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY, 193 /** 194 * Bacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with uncertain therapeutic effect. Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm) 195Projects: ISO 20776-1, ISO 20776-2 196 197 [Note 1: Bacterial strains are categorized as intermediate by applying the appropriate breakpoints in a defined phenotypic test system.] 198 199 [Note 2: This class of susceptibility implies that an infection due to the isolate can be appropriately treated in body sites where the drugs are physiologically concentrated or when a high dosage of drug can be used.] 200 201 [Note 3: This class also indicates a "buffer zone," to prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations.] 202 203 [Note 4: These breakpoints can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).] 204 */ 205 I, 206 /** 207 * The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder. 208 209 210 211 Deprecation Comment: 212 This antimicrobial susceptibility test interpretation concept is recommended by OO to be deprecated as it is no longer recommended for use in susceptibility testing by CLSI (reference CLSI document M100-S22; Vol. 32 No.3; CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Jan 2012). 213 */ 214 MS, 215 /** 216 * A category used for isolates for which only a susceptible interpretive criterion has been designated because of the absence or rare occurrence of resistant strains. Isolates that have MICs above or zone diameters below the value indicated for the susceptible breakpoint should be reported as non-susceptible. 217 218 NOTE 1: An isolate that is interpreted as non-susceptible does not necessarily mean that the isolate has a resistance mechanism. It is possible that isolates with MICs above the susceptible breakpoint that lack resistance mechanisms may be encountered within the wild-type distribution subsequent to the time the susceptible-only breakpoint is set. 219 220 NOTE 2: For strains yielding results in the "nonsusceptible" category, organism identification and antimicrobial susceptibility test results should be confirmed. 221 222 Synonym: decreased susceptibility. 223 */ 224 NS, 225 /** 226 * Bacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic failure. 227Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm) 228Projects: ISO 20776-1, ISO 20776-2 229 230 [Note 1: Bacterial strains are categorized as resistant by applying the appropriate breakpoints in a defined phenotypic test system.] 231 232 [Note 2: This breakpoint can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).] 233 */ 234 R, 235 /** 236 * A category for isolates where the bacteria (e.g. enterococci) are not susceptible in vitro to a combination therapy (e.g., high-level aminoglycoside and cell wall active agent). This is predictive that this combination therapy will not be effective. 237 238 239 Usage Note: Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside. 240 241 242 Open Issue: The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found. 243 */ 244 SYNR, 245 /** 246 * Bacterial strain inhibited by in vitro concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic success. 247Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm) 248Synonym (earlier term): Sensitive Projects: ISO 20776-1, ISO 20776-2 249 250 [Note 1: Bacterial strains are categorized as susceptible by applying the appropriate breakpoints in a defined phenotypic system.] 251 252 [Note 2: This breakpoint can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).] 253 */ 254 S, 255 /** 256 * A category that includes isolates with antimicrobial agent minimum inhibitory concentrations (MICs) that approach usually attainable blood and tissue levels and for which response rates may be lower than for susceptible isolates. 257 258 Reference: CLSI document M44-A2 2009 "Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline - second edition" - page 2. 259 */ 260 SDD, 261 /** 262 * A category for isolates where the bacteria (e.g. enterococci) are susceptible in vitro to a combination therapy (e.g., high-level aminoglycoside and cell wall active agent). This is predictive that this combination therapy will be effective. 263 264 265 Usage Note: Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside. 266 267 268 Open Issue: The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found. 269 */ 270 SYNS, 271 /** 272 * The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder. 273 274 275 276 Deprecation Comment: 277 This antimicrobial susceptibility test interpretation concept is recommended by OO to be deprecated as it is no longer recommended for use in susceptibility testing by CLSI (reference CLSI document M100-S22; Vol. 32 No.3; CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Jan 2012). 278 */ 279 VS, 280 /** 281 * The observation/test result is interpreted as being outside the inclusion range for a particular protocol within which the result is being reported. 282 283 284 Example: A positive result on a Hepatitis screening test. 285 Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. 286These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal "030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. 287Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held. 288 */ 289 EX, 290 /** 291 * The observation/test result is interpreted as being outside the inclusion range for a particular protocol within which the result is being reported. 292 293 294 Example: A positive result on a Hepatitis screening test. 295 Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal "030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held. 296 */ 297 HX, 298 /** 299 * The numeric observation/test result is interpreted as being below the low threshold value for a particular protocol within which the result is being reported. 300 301 Example: A Total White Blood Cell Count falling below a protocol-defined threshold value of 3000/mm^3 302 Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal "030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held. 303 */ 304 LX, 305 /** 306 * Interpretations of the presence or absence of a component / analyte or organism in a test or of a sign in a clinical observation. In keeping with laboratory data processing practice, these concepts provide a categorical interpretation of the "meaning" of the quantitative value for the same observation. 307 */ 308 OBSERVATIONINTERPRETATIONDETECTION, 309 /** 310 * The specified component / analyte, organism or clinical sign could neither be declared positive / negative nor detected / not detected by the performed test or procedure. 311 312 313 Usage Note: For example, if the specimen was degraded, poorly processed, or was missing the required anatomic structures, then "indeterminate" (i.e. "cannot be determined") is the appropriate response, not "equivocal". 314 */ 315 IND, 316 /** 317 * The test or procedure was successfully performed, but the results are borderline and can neither be declared positive / negative nor detected / not detected according to the current established criteria. 318 */ 319 E, 320 /** 321 * An absence finding of the specified component / analyte, organism or clinical sign based on the established threshold of the performed test or procedure. 322 323 [Note: Negative does not necessarily imply the complete absence of the specified item.] 324 */ 325 NEG, 326 /** 327 * The presence of the specified component / analyte, organism or clinical sign could not be determined within the limit of detection of the performed test or procedure. 328 */ 329 ND, 330 /** 331 * A presence finding of the specified component / analyte, organism or clinical sign based on the established threshold of the performed test or procedure. 332 */ 333 POS, 334 /** 335 * The measurement of the specified component / analyte, organism or clinical sign above the limit of detection of the performed test or procedure. 336 */ 337 DET, 338 /** 339 * Interpretation of the observed result taking into account additional information (contraindicators) about the patient's situation. Concepts in this category are mutually exclusive, i.e., at most one is allowed. 340 */ 341 OBSERVATIONINTERPRETATIONEXPECTATION, 342 /** 343 * This result has been evaluated in light of known contraindicators. Once those contraindicators have been taken into account the result is determined to be "Expected" (e.g., presence of drugs in a patient that is taking prescription medication for pain management). 344 */ 345 EXP, 346 /** 347 * This result has been evaluated in light of known contraindicators. Once those contraindicators have been taken into account the result is determined to be "Unexpected" (e.g., presence of non-prescribed drugs in a patient that is taking prescription medication for pain management). 348 */ 349 UNE, 350 /** 351 * Interpretations of the presence and level of reactivity of the specified component / analyte with the reagent in the performed laboratory test. 352 */ 353 REACTIVITYOBSERVATIONINTERPRETATION, 354 /** 355 * An absence finding used to indicate that the specified component / analyte did not react measurably with the reagent. 356 */ 357 NR, 358 /** 359 * A presence finding used to indicate that the specified component / analyte reacted with the reagent above the reliably measurable limit of the performed test. 360 */ 361 RR, 362 /** 363 * A weighted presence finding used to indicate that the specified component / analyte reacted with the reagent, but below the reliably measurable limit of the performed test. 364 */ 365 WR, 366 /** 367 * added to help the parsers 368 */ 369 NULL; 370 public static V3ObservationInterpretation fromCode(String codeString) throws FHIRException { 371 if (codeString == null || "".equals(codeString)) 372 return null; 373 if ("_GeneticObservationInterpretation".equals(codeString)) 374 return _GENETICOBSERVATIONINTERPRETATION; 375 if ("CAR".equals(codeString)) 376 return CAR; 377 if ("Carrier".equals(codeString)) 378 return CARRIER; 379 if ("_ObservationInterpretationChange".equals(codeString)) 380 return _OBSERVATIONINTERPRETATIONCHANGE; 381 if ("B".equals(codeString)) 382 return B; 383 if ("D".equals(codeString)) 384 return D; 385 if ("U".equals(codeString)) 386 return U; 387 if ("W".equals(codeString)) 388 return W; 389 if ("_ObservationInterpretationExceptions".equals(codeString)) 390 return _OBSERVATIONINTERPRETATIONEXCEPTIONS; 391 if ("<".equals(codeString)) 392 return LESS_THAN; 393 if (">".equals(codeString)) 394 return GREATER_THAN; 395 if ("AC".equals(codeString)) 396 return AC; 397 if ("IE".equals(codeString)) 398 return IE; 399 if ("QCF".equals(codeString)) 400 return QCF; 401 if ("TOX".equals(codeString)) 402 return TOX; 403 if ("_ObservationInterpretationNormality".equals(codeString)) 404 return _OBSERVATIONINTERPRETATIONNORMALITY; 405 if ("A".equals(codeString)) 406 return A; 407 if ("AA".equals(codeString)) 408 return AA; 409 if ("HH".equals(codeString)) 410 return HH; 411 if ("LL".equals(codeString)) 412 return LL; 413 if ("H".equals(codeString)) 414 return H; 415 if ("H>".equals(codeString)) 416 return H_; 417 if ("HU".equals(codeString)) 418 return HU; 419 if ("L".equals(codeString)) 420 return L; 421 if ("L<".equals(codeString)) 422 return L_; 423 if ("LU".equals(codeString)) 424 return LU; 425 if ("N".equals(codeString)) 426 return N; 427 if ("_ObservationInterpretationSusceptibility".equals(codeString)) 428 return _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY; 429 if ("I".equals(codeString)) 430 return I; 431 if ("MS".equals(codeString)) 432 return MS; 433 if ("NS".equals(codeString)) 434 return NS; 435 if ("R".equals(codeString)) 436 return R; 437 if ("SYN-R".equals(codeString)) 438 return SYNR; 439 if ("S".equals(codeString)) 440 return S; 441 if ("SDD".equals(codeString)) 442 return SDD; 443 if ("SYN-S".equals(codeString)) 444 return SYNS; 445 if ("VS".equals(codeString)) 446 return VS; 447 if ("EX".equals(codeString)) 448 return EX; 449 if ("HX".equals(codeString)) 450 return HX; 451 if ("LX".equals(codeString)) 452 return LX; 453 if ("ObservationInterpretationDetection".equals(codeString)) 454 return OBSERVATIONINTERPRETATIONDETECTION; 455 if ("IND".equals(codeString)) 456 return IND; 457 if ("E".equals(codeString)) 458 return E; 459 if ("NEG".equals(codeString)) 460 return NEG; 461 if ("ND".equals(codeString)) 462 return ND; 463 if ("POS".equals(codeString)) 464 return POS; 465 if ("DET".equals(codeString)) 466 return DET; 467 if ("ObservationInterpretationExpectation".equals(codeString)) 468 return OBSERVATIONINTERPRETATIONEXPECTATION; 469 if ("EXP".equals(codeString)) 470 return EXP; 471 if ("UNE".equals(codeString)) 472 return UNE; 473 if ("ReactivityObservationInterpretation".equals(codeString)) 474 return REACTIVITYOBSERVATIONINTERPRETATION; 475 if ("NR".equals(codeString)) 476 return NR; 477 if ("RR".equals(codeString)) 478 return RR; 479 if ("WR".equals(codeString)) 480 return WR; 481 throw new FHIRException("Unknown V3ObservationInterpretation code '"+codeString+"'"); 482 } 483 public String toCode() { 484 switch (this) { 485 case _GENETICOBSERVATIONINTERPRETATION: return "_GeneticObservationInterpretation"; 486 case CAR: return "CAR"; 487 case CARRIER: return "Carrier"; 488 case _OBSERVATIONINTERPRETATIONCHANGE: return "_ObservationInterpretationChange"; 489 case B: return "B"; 490 case D: return "D"; 491 case U: return "U"; 492 case W: return "W"; 493 case _OBSERVATIONINTERPRETATIONEXCEPTIONS: return "_ObservationInterpretationExceptions"; 494 case LESS_THAN: return "<"; 495 case GREATER_THAN: return ">"; 496 case AC: return "AC"; 497 case IE: return "IE"; 498 case QCF: return "QCF"; 499 case TOX: return "TOX"; 500 case _OBSERVATIONINTERPRETATIONNORMALITY: return "_ObservationInterpretationNormality"; 501 case A: return "A"; 502 case AA: return "AA"; 503 case HH: return "HH"; 504 case LL: return "LL"; 505 case H: return "H"; 506 case H_: return "H>"; 507 case HU: return "HU"; 508 case L: return "L"; 509 case L_: return "L<"; 510 case LU: return "LU"; 511 case N: return "N"; 512 case _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY: return "_ObservationInterpretationSusceptibility"; 513 case I: return "I"; 514 case MS: return "MS"; 515 case NS: return "NS"; 516 case R: return "R"; 517 case SYNR: return "SYN-R"; 518 case S: return "S"; 519 case SDD: return "SDD"; 520 case SYNS: return "SYN-S"; 521 case VS: return "VS"; 522 case EX: return "EX"; 523 case HX: return "HX"; 524 case LX: return "LX"; 525 case OBSERVATIONINTERPRETATIONDETECTION: return "ObservationInterpretationDetection"; 526 case IND: return "IND"; 527 case E: return "E"; 528 case NEG: return "NEG"; 529 case ND: return "ND"; 530 case POS: return "POS"; 531 case DET: return "DET"; 532 case OBSERVATIONINTERPRETATIONEXPECTATION: return "ObservationInterpretationExpectation"; 533 case EXP: return "EXP"; 534 case UNE: return "UNE"; 535 case REACTIVITYOBSERVATIONINTERPRETATION: return "ReactivityObservationInterpretation"; 536 case NR: return "NR"; 537 case RR: return "RR"; 538 case WR: return "WR"; 539 case NULL: return null; 540 default: return "?"; 541 } 542 } 543 public String getSystem() { 544 return "http://hl7.org/fhir/v3/ObservationInterpretation"; 545 } 546 public String getDefinition() { 547 switch (this) { 548 case _GENETICOBSERVATIONINTERPRETATION: return "Codes that specify interpretation of genetic analysis, such as \"positive\", \"negative\", \"carrier\", \"responsive\", etc."; 549 case CAR: return "The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder."; 550 case CARRIER: return "The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder.\r\n\n \n \n Deprecation Comment: \n This code is currently the same string as the print name for this concept and is inconsistent with the conventions being used for the other codes in the coding system, as it is a full word with initial capitalization, rather than an all upper case mnemonic. The recommendation from OO is to deprecate the code \"Carrier\" and to add \"CAR\" as the new active code representation for this concept."; 551 case _OBSERVATIONINTERPRETATIONCHANGE: return "Interpretations of change of quantity and/or severity. At most one of B or W and one of U or D allowed."; 552 case B: return "The current result or observation value has improved compared to the previous result or observation value (the change is significant as defined in the respective test procedure).\r\n\n [Note: This can be applied to quantitative or qualitative observations.]"; 553 case D: return "The current result has decreased from the previous result for a quantitative observation (the change is significant as defined in the respective test procedure)."; 554 case U: return "The current result has increased from the previous result for a quantitative observation (the change is significant as defined in the respective test procedure)."; 555 case W: return "The current result or observation value has degraded compared to the previous result or observation value (the change is significant as defined in the respective test procedure).\r\n\n [Note: This can be applied to quantitative or qualitative observations.]"; 556 case _OBSERVATIONINTERPRETATIONEXCEPTIONS: return "Technical exceptions resulting in the inability to provide an interpretation. At most one allowed. Does not imply normality or severity."; 557 case LESS_THAN: return "The result is below the minimum detection limit (the test procedure or equipment is the limiting factor).\r\n\n Synonyms: Below analytical limit, low off scale."; 558 case GREATER_THAN: return "The result is above the maximum quantifiable limit (the test procedure or equipment is the limiting factor).\r\n\n Synonyms: Above analytical limit, high off scale."; 559 case AC: return "A valid result cannot be obtained for the specified component / analyte due to the presence of anti-complementary substances in the sample."; 560 case IE: return "There is insufficient evidence that the species in question is a good target for therapy with the drug. A categorical interpretation is not possible.\r\n\n [Note: A MIC with \"IE\" and/or a comment may be reported (without an accompanying S, I or R-categorization).]"; 561 case QCF: return "A result cannot be considered valid for the specified component / analyte or organism due to failure in the quality control testing component."; 562 case TOX: return "A valid result cannot be obtained for the specified organism or cell line due to the presence of cytotoxic substances in the sample or culture."; 563 case _OBSERVATIONINTERPRETATIONNORMALITY: return "Interpretation of normality or degree of abnormality (including critical or \"alert\" level). Concepts in this category are mutually exclusive, i.e., at most one is allowed."; 564 case A: return "The result or observation value is outside the reference range or expected norm (as defined for the respective test procedure).\r\n\n [Note: Typically applies to non-numeric results.]"; 565 case AA: return "The result or observation value is outside a reference range or expected norm at a level at which immediate action should be considered for patient safety (as defined for the respective test procedure).\r\n\n [Note: Typically applies to non-numeric results. Analogous to critical/panic limits for numeric results.]"; 566 case HH: return "The result for a quantitative observation is above a reference level at which immediate action should be considered for patient safety (as defined for the respective test procedure).\r\n\n Synonym: Above upper panic limits."; 567 case LL: return "The result for a quantitative observation is below a reference level at which immediate action should be considered for patient safety (as defined for the respective test procedure).\r\n\n Synonym: Below lower panic limits."; 568 case H: return "The result for a quantitative observation is above the upper limit of the reference range (as defined for the respective test procedure).\r\n\n Synonym: Above high normal"; 569 case H_: return "A test result that is significantly higher than the reference (normal) or therapeutic interval, but has not reached the critically high value and might need special attention, as defined by the laboratory or the clinician.[Note: This level is situated between 'H' and 'HH'.]\r\n\n \n Deprecation Comment: The code 'H>' is being deprecated in order to align with the use of the code 'HU' for \"Very high\" in V2 Table 0078 \"Interpretation Codes\".\r\n\n [Note: The use of code 'H>' is non-preferred, as this code is deprecated and on track to be retired; use code 'HU' instead."; 570 case HU: return "A test result that is significantly higher than the reference (normal) or therapeutic interval, but has not reached the critically high value and might need special attention, as defined by the laboratory or the clinician."; 571 case L: return "The result for a quantitative observation is below the lower limit of the reference range (as defined for the respective test procedure).\r\n\n Synonym: Below low normal"; 572 case L_: return "A test result that is significantly lower than the reference (normal) or therapeutic interval, but has not reached the critically low value and might need special attention, as defined by the laboratory or the clinician.[Note: This level is situated between 'L' and 'LL'.]\r\n\n \n Deprecation Comment: The code 'L<' is being deprecated in order to align with the use of the code 'LU' for \"Very low\" in V2 Table 0078 \"Interpretation Codes\".\r\n\n [Note: The use of code 'L<' is non-preferred, as this code is deprecated and on track to be retired; use code 'LU' instead."; 573 case LU: return "A test result that is significantly lower than the reference (normal) or therapeutic interval, but has not reached the critically low value and might need special attention, as defined by the laboratory or the clinician."; 574 case N: return "The result or observation value is within the reference range or expected norm (as defined for the respective test procedure).\r\n\n [Note: Applies to numeric or non-numeric results.]"; 575 case _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY: return "Interpretations of anti-microbial susceptibility testing results (microbiology). At most one allowed."; 576 case I: return "Bacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with uncertain therapeutic effect. Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm)\nProjects: ISO 20776-1, ISO 20776-2\r\n\n [Note 1: Bacterial strains are categorized as intermediate by applying the appropriate breakpoints in a defined phenotypic test system.]\r\n\n [Note 2: This class of susceptibility implies that an infection due to the isolate can be appropriately treated in body sites where the drugs are physiologically concentrated or when a high dosage of drug can be used.]\r\n\n [Note 3: This class also indicates a \"buffer zone,\" to prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations.]\r\n\n [Note 4: These breakpoints can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).]"; 577 case MS: return "The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder.\r\n\n \n \n Deprecation Comment: \n This antimicrobial susceptibility test interpretation concept is recommended by OO to be deprecated as it is no longer recommended for use in susceptibility testing by CLSI (reference CLSI document M100-S22; Vol. 32 No.3; CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Jan 2012)."; 578 case NS: return "A category used for isolates for which only a susceptible interpretive criterion has been designated because of the absence or rare occurrence of resistant strains. Isolates that have MICs above or zone diameters below the value indicated for the susceptible breakpoint should be reported as non-susceptible.\r\n\n NOTE 1: An isolate that is interpreted as non-susceptible does not necessarily mean that the isolate has a resistance mechanism. It is possible that isolates with MICs above the susceptible breakpoint that lack resistance mechanisms may be encountered within the wild-type distribution subsequent to the time the susceptible-only breakpoint is set. \r\n\n NOTE 2: For strains yielding results in the \"nonsusceptible\" category, organism identification and antimicrobial susceptibility test results should be confirmed.\r\n\n Synonym: decreased susceptibility."; 579 case R: return "Bacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic failure.\nReference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm) \nProjects: ISO 20776-1, ISO 20776-2\r\n\n [Note 1: Bacterial strains are categorized as resistant by applying the appropriate breakpoints in a defined phenotypic test system.]\r\n\n [Note 2: This breakpoint can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).]"; 580 case SYNR: return "A category for isolates where the bacteria (e.g. enterococci) are not susceptible in vitro to a combination therapy (e.g., high-level aminoglycoside and cell wall active agent). This is predictive that this combination therapy will not be effective. \r\n\n \n Usage Note: Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside.\r\n\n \n Open Issue: The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found."; 581 case S: return "Bacterial strain inhibited by in vitro concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic success.\nReference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm)\nSynonym (earlier term): Sensitive Projects: ISO 20776-1, ISO 20776-2\r\n\n [Note 1: Bacterial strains are categorized as susceptible by applying the appropriate breakpoints in a defined phenotypic system.]\r\n\n [Note 2: This breakpoint can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).]"; 582 case SDD: return "A category that includes isolates with antimicrobial agent minimum inhibitory concentrations (MICs) that approach usually attainable blood and tissue levels and for which response rates may be lower than for susceptible isolates.\r\n\n Reference: CLSI document M44-A2 2009 \"Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline - second edition\" - page 2."; 583 case SYNS: return "A category for isolates where the bacteria (e.g. enterococci) are susceptible in vitro to a combination therapy (e.g., high-level aminoglycoside and cell wall active agent). This is predictive that this combination therapy will be effective. \r\n\n \n Usage Note: Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside.\r\n\n \n Open Issue: The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found."; 584 case VS: return "The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder.\r\n\n \n \n Deprecation Comment: \n This antimicrobial susceptibility test interpretation concept is recommended by OO to be deprecated as it is no longer recommended for use in susceptibility testing by CLSI (reference CLSI document M100-S22; Vol. 32 No.3; CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Jan 2012)."; 585 case EX: return "The observation/test result is interpreted as being outside the inclusion range for a particular protocol within which the result is being reported.\n\r\n\n Example: A positive result on a Hepatitis screening test.\n Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects.\nThese concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal \"030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455\". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes.\nMembers of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held."; 586 case HX: return "The observation/test result is interpreted as being outside the inclusion range for a particular protocol within which the result is being reported.\n\r\n\n Example: A positive result on a Hepatitis screening test.\n Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal \"030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455\". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held."; 587 case LX: return "The numeric observation/test result is interpreted as being below the low threshold value for a particular protocol within which the result is being reported.\r\n\n Example: A Total White Blood Cell Count falling below a protocol-defined threshold value of 3000/mm^3\n Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal \"030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455\". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held."; 588 case OBSERVATIONINTERPRETATIONDETECTION: return "Interpretations of the presence or absence of a component / analyte or organism in a test or of a sign in a clinical observation. In keeping with laboratory data processing practice, these concepts provide a categorical interpretation of the \"meaning\" of the quantitative value for the same observation."; 589 case IND: return "The specified component / analyte, organism or clinical sign could neither be declared positive / negative nor detected / not detected by the performed test or procedure.\r\n\n \n Usage Note: For example, if the specimen was degraded, poorly processed, or was missing the required anatomic structures, then \"indeterminate\" (i.e. \"cannot be determined\") is the appropriate response, not \"equivocal\"."; 590 case E: return "The test or procedure was successfully performed, but the results are borderline and can neither be declared positive / negative nor detected / not detected according to the current established criteria."; 591 case NEG: return "An absence finding of the specified component / analyte, organism or clinical sign based on the established threshold of the performed test or procedure.\r\n\n [Note: Negative does not necessarily imply the complete absence of the specified item.]"; 592 case ND: return "The presence of the specified component / analyte, organism or clinical sign could not be determined within the limit of detection of the performed test or procedure."; 593 case POS: return "A presence finding of the specified component / analyte, organism or clinical sign based on the established threshold of the performed test or procedure."; 594 case DET: return "The measurement of the specified component / analyte, organism or clinical sign above the limit of detection of the performed test or procedure."; 595 case OBSERVATIONINTERPRETATIONEXPECTATION: return "Interpretation of the observed result taking into account additional information (contraindicators) about the patient's situation. Concepts in this category are mutually exclusive, i.e., at most one is allowed."; 596 case EXP: return "This result has been evaluated in light of known contraindicators. Once those contraindicators have been taken into account the result is determined to be \"Expected\" (e.g., presence of drugs in a patient that is taking prescription medication for pain management)."; 597 case UNE: return "This result has been evaluated in light of known contraindicators. Once those contraindicators have been taken into account the result is determined to be \"Unexpected\" (e.g., presence of non-prescribed drugs in a patient that is taking prescription medication for pain management)."; 598 case REACTIVITYOBSERVATIONINTERPRETATION: return "Interpretations of the presence and level of reactivity of the specified component / analyte with the reagent in the performed laboratory test."; 599 case NR: return "An absence finding used to indicate that the specified component / analyte did not react measurably with the reagent."; 600 case RR: return "A presence finding used to indicate that the specified component / analyte reacted with the reagent above the reliably measurable limit of the performed test."; 601 case WR: return "A weighted presence finding used to indicate that the specified component / analyte reacted with the reagent, but below the reliably measurable limit of the performed test."; 602 case NULL: return null; 603 default: return "?"; 604 } 605 } 606 public String getDisplay() { 607 switch (this) { 608 case _GENETICOBSERVATIONINTERPRETATION: return "GeneticObservationInterpretation"; 609 case CAR: return "Carrier"; 610 case CARRIER: return "Carrier"; 611 case _OBSERVATIONINTERPRETATIONCHANGE: return "ObservationInterpretationChange"; 612 case B: return "Better"; 613 case D: return "Significant change down"; 614 case U: return "Significant change up"; 615 case W: return "Worse"; 616 case _OBSERVATIONINTERPRETATIONEXCEPTIONS: return "ObservationInterpretationExceptions"; 617 case LESS_THAN: return "Off scale low"; 618 case GREATER_THAN: return "Off scale high"; 619 case AC: return "Anti-complementary substances present"; 620 case IE: return "Insufficient evidence"; 621 case QCF: return "Quality control failure"; 622 case TOX: return "Cytotoxic substance present"; 623 case _OBSERVATIONINTERPRETATIONNORMALITY: return "ObservationInterpretationNormality"; 624 case A: return "Abnormal"; 625 case AA: return "Critical abnormal"; 626 case HH: return "Critical high"; 627 case LL: return "Critical low"; 628 case H: return "High"; 629 case H_: return "Significantly high"; 630 case HU: return "Significantly high"; 631 case L: return "Low"; 632 case L_: return "Significantly low"; 633 case LU: return "Significantly low"; 634 case N: return "Normal"; 635 case _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY: return "ObservationInterpretationSusceptibility"; 636 case I: return "Intermediate"; 637 case MS: return "moderately susceptible"; 638 case NS: return "Non-susceptible"; 639 case R: return "Resistant"; 640 case SYNR: return "Synergy - resistant"; 641 case S: return "Susceptible"; 642 case SDD: return "Susceptible-dose dependent"; 643 case SYNS: return "Synergy - susceptible"; 644 case VS: return "very susceptible"; 645 case EX: return "outside threshold"; 646 case HX: return "above high threshold"; 647 case LX: return "below low threshold"; 648 case OBSERVATIONINTERPRETATIONDETECTION: return "ObservationInterpretationDetection"; 649 case IND: return "Indeterminate"; 650 case E: return "Equivocal"; 651 case NEG: return "Negative"; 652 case ND: return "Not detected"; 653 case POS: return "Positive"; 654 case DET: return "Detected"; 655 case OBSERVATIONINTERPRETATIONEXPECTATION: return "ObservationInterpretationExpectation"; 656 case EXP: return "Expected"; 657 case UNE: return "Unexpected"; 658 case REACTIVITYOBSERVATIONINTERPRETATION: return "ReactivityObservationInterpretation"; 659 case NR: return "Non-reactive"; 660 case RR: return "Reactive"; 661 case WR: return "Weakly reactive"; 662 case NULL: return null; 663 default: return "?"; 664 } 665 } 666 667 668}